Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping

Y Kakuta, Y Kinouchi, T Shimosegawa - Journal of Gastroenterology, 2018 - Springer
Abstract The thiopurine drugs 6-mercaptopurine (6-MP) and azathiopurine (AZA) are widely
used to treat inflammatory bowel disease. However, the incidence of adverse reactions is …

Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring

SZ Lim, EW Chua - Frontiers in pharmacology, 2018 - frontiersin.org
Azathioprine and 6-mercaptopurine, often referred to as thiopurine compounds, are
commonly used in the management of inflammatory bowel disease. However, patients …

NUDT15 hydrolyzes 6-thio-deoxyGTP to mediate the anticancer efficacy of 6-thioguanine

NCK Valerie, A Hagenkort, BDG Page, G Masuyer… - Cancer research, 2016 - AACR
Thiopurines are a standard treatment for childhood leukemia, but like all chemotherapeutics,
their use is limited by inherent or acquired resistance in patients. Recently, the nucleoside …

Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry

T Moriyama, YL Yang, R Nishii, H Ariffin… - Blood, The Journal …, 2017 - ashpublications.org
Prolonged exposure to thiopurines (eg, mercaptopurine [MP]) is essential for curative
therapy in acute lymphoblastic leukemia (ALL), but is also associated with frequent dose …

Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?

H Zhou, L Li, P Yang, L Yang, JE Zheng, Y Zhou, Y Han - BMC cancer, 2018 - Springer
Abstract Background 6-mercaptopurine (6-MP) contributes substantially to remarkable
improvement in the survival of childhood acute lymphoblastic leukemia (ALL) patients …

Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review

D Desai, A Jena, V Sharma, T Hibi - Expert Review of Clinical …, 2023 - Taylor & Francis
Introduction Thiopurine toxicity is related to genetic polymorphism. Thiopurine
methyltransferase (TPMT) variants do not explain thiopurine toxicity in more than half of …

Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia

R Choi, I Sohn, MJ Kim, HI Woo, JW Lee… - British journal of …, 2019 - Wiley Online Library
Aims We aimed to investigate the impact of various genetic polymorphisms affecting
thiopurine metabolism pathways and toxicity in paediatric acute lymphoblastic leukaemia …

The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment

S Rudin, M Marable, RS Huang - Genomics, Proteomics and …, 2017 - academic.oup.com
Pediatric acute lymphoblastic leukemia (ALL) affects a substantial number of children every
year and requires a long and rigorous course of chemotherapy treatments in three stages …

Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia

S Khera, A Trehan, P Bhatia, M Singh, D Bansal… - Cancer Chemotherapy …, 2019 - Springer
Abstract Purpose Toxicity of 6-Mercaptopurine (6MP) is related to single nucleotide
polymorphism (SNP) in genes coding for metabolizing enzymes, with TPMT analysis being …

Nucleoside diphosphate‐linked moiety X‐type motif 15 C415T variant as a predictor for thiopurine‐induced toxicity in Indian patients

SAV Shah, M Paradkar, D Desai… - Journal of …, 2017 - Wiley Online Library
Abstract Background and Aim Interindividual variation seen in the thiopurine metabolism is
attributed to the genetic variant in thiopurine methyltransferase (TPMT) gene leading to …